Vanessa Asoh Shu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vanessa Asoh Shu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Fidele Ntie-Kang
University of Buea
4 shared publications - Donatus Bekindaka Eni
Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon
3 shared publications - Clovis S. Metuge
Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon
2 shared publications - Jude Y. Betow
Center for Drug Discovery, Faculty of Science, University of Buea, Buea, Cameroon
2 shared publications - Oyere Tanyi Ebob
School of Science and Technology (SST), Nottingham Trent University Department of Chemistry and Forensics NG1 4FQ Nottingham
2 shared publications - Simeon Akame
Faculty of Health Sciences, University of Buea Department of Clinical Microbiology Buea CM00237
2 shared publications
Latest Publications
- Open Access
- 17 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1336-D1344
African Natural Products Database (ANPDB): A resource for exploring the therapeutic potential of natural compounds from Africa
The African Natural Products Database (ANPDB) is a comprehensive repository currently encompassing over 11 000 natural compounds sourced from diverse species across the African continent. ANPDB integrates both experimental and predicted NMR and MS data to enhance compound annotation and facilitate dereplication, utilizing machine learning algorithms for spectral simulation and fragment prediction. The database offers a range of methods for compound structure search, including substructure matching, chemical similarity analysis, and property-based filtering, empowering users to efficiently explore chemical diversity. ANPDB also compiles detailed metadata on the traditional medicinal uses of source organisms, linking ethnobotanical knowledge with chemical and biological data. By consolidating information on biological sources, bioactivities, traditional applications, and bibliographic references (currently ranging from 1961 to 2024), ANPDB provides a robust platform for drug discovery, natural products research, and the exploration of Africa’s unique chemical and medicinal biodiversity. The database is open access, and the entire dataset and metadata are available for download and for computer-aided drug design endeavours. Link to the website: https://african-compounds.org
- 17 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1336-D1344
Open AccessAfrican Natural Products Database (ANPDB): A resource for exploring the therapeutic potential of natural compounds from Africa
The African Natural Products Database (ANPDB) is a comprehensive repository currently encompassing over 11 000 natural compounds sourced from diverse species across the African continent. ANPDB integrates both experimental and predicted NMR and MS data to enhance compound annotation and facilitate dereplication, utilizing machine learning algorithms for spectral simulation and fragment prediction. The database offers a range of methods for compound structure search, including substructure matching, chemical similarity analysis, and property-based filtering, empowering users to efficiently explore chemical diversity. ANPDB also compiles detailed metadata on the traditional medicinal uses of source organisms, linking ethnobotanical knowledge with chemical and biological data. By consolidating information on biological sources, bioactivities, traditional applications, and bibliographic references (currently ranging from 1961 to 2024), ANPDB provides a robust platform for drug discovery, natural products research, and the exploration of Africa’s unique chemical and medicinal biodiversity. The database is open access, and the entire dataset and metadata are available for download and for computer-aided drug design endeavours. Link to the website: https://african-compounds.org
- Open Access
- 23 November 2024
- Published by Wiley in Molecular Informatics
- Vol. 44 (1) , e202400293
The Chemical Space Spanned by Manually Curated Datasets of Natural and Synthetic Compounds with Activities against SARS‐CoV‐2
Diseases caused by viruses are challenging to contain, as their outbreak and spread could be very sudden, compounded by rapid mutations, making the development of drugs and vaccines a continued endeavour that requires fast discovery and preparedness. Targeting viral infections with small molecules remains one of the treatment options to reduce transmission and the disease burden. A lesson learned from the recent coronavirus disease (COVID‐19) is to collect ready‐to‐screen small molecule libraries in preparation for the next viral outbreak, and potentially find a clinical candidate before it becomes a pandemic. Public availability of diverse compound libraries, well annotated in terms of chemical structures and scaffolds, modes of action, and bioactivities are, therefore, crucial to ensure the participation of academic laboratories in these screening efforts, especially in resource‐limited settings where synthesis, testing and computing capacity are scarce. Here, we demonstrate a low‐resource approach to populate the chemical space of naturally occurring and synthetic small molecules that have shown in vitro and/or in vivo activities against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its target proteins. We have manually curated two datasets of small molecules (naturally occurring and synthetically derived) by reading and collecting (hand‐curating) the published literature. Information from the literature reveals that a majority of the reported SARS‐CoV‐2 compounds act by inhibiting the main protease, while 25% of the compounds currently have no known target. Scaffold analysis and principal component analysis revealed that the most common scaffolds in the datasets are quite distinct. We then expanded the initially manually curated dataset of over 1200 compounds via an ultra‐large scale 2D and 3D similarity search, obtaining an expanded collection of over 150 k purchasable compounds. The spanned chemical space significantly extends beyond that of a commercially available coronavirus library of more than 20 k small molecules and constitutes a good starting collection for virtual screening campaigns given its manageable size and proximity to hand‐curated compounds.
- 23 November 2024
- Published by Wiley in Molecular Informatics
- Vol. 44 (1) , e202400293
Open AccessThe Chemical Space Spanned by Manually Curated Datasets of Natural and Synthetic Compounds with Activities against SARS‐CoV‐2
Diseases caused by viruses are challenging to contain, as their outbreak and spread could be very sudden, compounded by rapid mutations, making the development of drugs and vaccines a continued endeavour that requires fast discovery and preparedness. Targeting viral infections with small molecules remains one of the treatment options to reduce transmission and the disease burden. A lesson learned from the recent coronavirus disease (COVID‐19) is to collect ready‐to‐screen small molecule libraries in preparation for the next viral outbreak, and potentially find a clinical candidate before it becomes a pandemic. Public availability of diverse compound libraries, well annotated in terms of chemical structures and scaffolds, modes of action, and bioactivities are, therefore, crucial to ensure the participation of academic laboratories in these screening efforts, especially in resource‐limited settings where synthesis, testing and computing capacity are scarce. Here, we demonstrate a low‐resource approach to populate the chemical space of naturally occurring and synthetic small molecules that have shown in vitro and/or in vivo activities against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its target proteins. We have manually curated two datasets of small molecules (naturally occurring and synthetically derived) by reading and collecting (hand‐curating) the published literature. Information from the literature reveals that a majority of the reported SARS‐CoV‐2 compounds act by inhibiting the main protease, while 25% of the compounds currently have no known target. Scaffold analysis and principal component analysis revealed that the most common scaffolds in the datasets are quite distinct. We then expanded the initially manually curated dataset of over 1200 compounds via an ultra‐large scale 2D and 3D similarity search, obtaining an expanded collection of over 150 k purchasable compounds. The spanned chemical space significantly extends beyond that of a commercially available coronavirus library of more than 20 k small molecules and constitutes a good starting collection for virtual screening campaigns given its manageable size and proximity to hand‐curated compounds.
- Open Access
- 4 June 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (2) , 1737-1760
A survey of isatin hybrids and their biological properties
The emergence of diverse infections worldwide, which is a serious global threat to human existence, necessitates the urgent development of novel therapeutic candidates that can combat these diseases with efficacy. Molecular hybridization has been established as an efficient technique in designing bioactive molecules capable of fighting infections. Isatin, a core nucleus of an array of compounds with diverse biological properties can be modified at different positions leading to the creation of novel drug targets, is an active area of medicinal chemistry. This review containing published articles from 2005 to 2022 highlights isatin hybrids which have been synthesized and reported in the literature alongside a discussion on their biological properties. The enriched structure–activity relationship studies discussed provides insights for the rational design of novel isatin hybrids with tailored biological properties as effective therapeutic candidates inspired by nature.
- 4 June 2024
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (2) , 1737-1760
Open AccessA survey of isatin hybrids and their biological properties
The emergence of diverse infections worldwide, which is a serious global threat to human existence, necessitates the urgent development of novel therapeutic candidates that can combat these diseases with efficacy. Molecular hybridization has been established as an efficient technique in designing bioactive molecules capable of fighting infections. Isatin, a core nucleus of an array of compounds with diverse biological properties can be modified at different positions leading to the creation of novel drug targets, is an active area of medicinal chemistry. This review containing published articles from 2005 to 2022 highlights isatin hybrids which have been synthesized and reported in the literature alongside a discussion on their biological properties. The enriched structure–activity relationship studies discussed provides insights for the rational design of novel isatin hybrids with tailored biological properties as effective therapeutic candidates inspired by nature.
- Open Access
- 16 January 2024
- Published by MDPI AG in Preprints.org
A Survey of Isatin Hybrids and their Biological Properties
The emergence of diverse infections worldwide, which is a serious global threat to human existence, necessitate the urgent development of novel therapeutic candidates that can combat these diseases with efficacy. Isatin, a secondary metabolite from tryptophan is considered a privileged scaffold and favorable pharmacophore with a unique structural moiety and varied chemical and biological properties resulting in its widespread applications by medicinal chemists. Molecular hybridization is one of the most common and important techniques use in the synthesis of their bioactive hybrids in drug discovery. This review containing published articles from 2005 to 2022 focuses on isatin hybrids which have been synthesized and reported in the literature alongside a discussion on their biological properties. The purpose of this review is to set up the direction for the design and development of isatin-hybrids with tailored biological properties as effective therapeutic candidates inspired by nature.
- 16 January 2024
- Published by MDPI AG in Preprints.org
Open AccessA Survey of Isatin Hybrids and their Biological Properties
The emergence of diverse infections worldwide, which is a serious global threat to human existence, necessitate the urgent development of novel therapeutic candidates that can combat these diseases with efficacy. Isatin, a secondary metabolite from tryptophan is considered a privileged scaffold and favorable pharmacophore with a unique structural moiety and varied chemical and biological properties resulting in its widespread applications by medicinal chemists. Molecular hybridization is one of the most common and important techniques use in the synthesis of their bioactive hybrids in drug discovery. This review containing published articles from 2005 to 2022 focuses on isatin hybrids which have been synthesized and reported in the literature alongside a discussion on their biological properties. The purpose of this review is to set up the direction for the design and development of isatin-hybrids with tailored biological properties as effective therapeutic candidates inspired by nature.